aap Implantate AG (“aap”) announces the conclusion of a distribution contract for its LOQTEQ® products with a leading US healthcare service provider.
The contract initially provides for a 12-month pilot phase in which the contractual partner will sell LOQTEQ® products in a number of selected US states. If it proves to be successful, distribution will gradually be rolled out to further states. aap relies on a hybrid distribution strategy in North America. Distribution takes place both via distribution agents and through partnerships with global orthopaedic and medical technology companies.
The conclusion of the distribution contract represents further important progress in the aimed distribution focus on established markets such as North America, the DACH region and further European countries. The partnership with this new customer will additionally support the dynamic development in North America to date and thus contribute to the further planned sales growth in this strategic core market.
This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap’s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments
For further information, please contact:
aap Implantate AG
Lorenzweg 5
12099 Berlin
Fabian Franke
Manager Investor Relations
Tel.: +49 (0)30 / 750 19 134
Fax: +49 (0)30 / 750 19 290
Contact
